METHODS AND ORGANISMS WITH INCREASED CARBON FLUX EFFICIENCIES

1 . A non-naturally occurring microbial organism comprising a genetic alteration selected from the group consisting of:

(1) attenuation of cydA or cydB, and one or more of a genetic alteration selected from the group consisting of:

(a) a genetic alteration that increases expression of a protein encoded by pntAB;

(b) attenuation of the protein encoded by pykF;

(c) attenuation of the protein encoded by sucCD;

(d) attenuation of the protein encoded by yciA;

(e) a genetic alteration that increases expression of a protein encoded by ackA and a protein encoded by pta;

(f) a genetic alteration that increases expression of a protein encoded by cyoB;

(g) attenuation of the protein encoded by pykA;

(h) attenuation of the protein encoded by arcA;

(i) attenuation of the protein encoded by crr;

(j) attenuation of the protein encoded by clpA; and

(k) attenuation of the protein encoded by menC; and

(2) a genetic alteration selected from the group consisting of

(a) attenuation of the proteins encoded by sucCD and yciA;

(b) attenuation of the proteins encoded by sucCD and yciA, and having a genetic alteration that increases expression of a protein encoded by pntAB;

(c) attenuation of the proteins encoded by sucCD and yciA, and having a genetic alteration that increases expression of a protein encoded by cyoB;

(d) attenuation of the proteins encoded by sucCD, yciA and cydA or cydB, and having a genetic alteration that increases expression of a protein encoded by cyoB;

(e) attenuation of the proteins encoded by sucCD, yciA and menC and having a genetic alteration that increases expression of a protein encoded by cyoB;

(f) attenuation of the proteins encoded by sucCD, yciA, cydA or cydB and menC and having a genetic alteration that increases expression of an protein encoded by cyoB;

(g) attenuation of the proteins encoded by sucCD and cydA or cydB;

(h) attenuation of the proteins encoded by sucCD and cydA or cydB and pykF;

(i) attenuation of the proteins encoded by sucCD and cydA or cydB, and having a genetic alteration that increases expression of a protein encoded by pntAB;

(j) attenuation of the proteins encoded by sucCD and cydA or cydB and pykF, and having a genetic alteration that increases expression of a protein encoded by pntAB;

(k) attenuation of the proteins encoded by sucCD, yciA and cydA or cydB;

(l) attenuation of the proteins encoded by sucCD, yciA and cydA or cydB and pykF;

(m) attenuation of the proteins encoded by sucCD, yciA and cydA or cydB, and having a genetic alteration that increases expression of a protein encoded by pntAB;

(n) attenuation of the proteins encoded by sucCD, yciA and cydA or cydB and pykF, and having a genetic alteration that increases expression of a protein encoded by pntAB;

(o) attenuation of the proteins encoded by sucCD, yciA, and cydA or cydB and menC;

(p) attenuation of the proteins encoded by sucCD, yciA and cydA or cydB and menC, and having a genetic alteration that increases expression of a protein encoded by pntAB;

(q) attenuation of the proteins encoded by sucCD and pykF, and having a genetic alteration that increases expression of a protein encoded by pntAB;

(r) attenuation of the protein encoded by clpA;

(s) attenuation of the protein encoded by menC;

(t) attenuation of the protein encoded by menC and cydA or cydB;

(u) attenuation of the protein encoded by pykF and/or pykA;

(v) having a genetic alteration that increases expression of a protein encoded by pntAB;

(w) attenuation of cydA or cydB and sucCD, arcA and crr, and having a genetic alteration that increases expression of a protein encoded by ackA and pta;

(x) attenuation of cydA or cydB and arcA;

(y) attenuation of cydA or cydB, and having a genetic alteration that increases expression of a protein encoded by pntAB;

(z) attenuation of cydA or cydB and pykF; and

(aa) attenuation of cydA or cydB and pykF, and having a genetic alteration that increases expression of a protein encoded by pntAB.

2 .- 7 . (canceled)

8 . A method of producing a bioderived compound comprising culturing a non-naturally occurring microbial organism of claim 1 for a sufficient period of time under conditions sufficient to produce said bioderived compound.

9 . A bioderived compound produced by the non-naturally occurring microbial organism of claim 1 .

10 . A non-naturally occurring microbial organism comprising a first attenuation of a succinyl-CoA synthetase or transferase and at least a second attenuation of a succinyl-CoA converting enzyme or a gene encoding a succinate producing enzyme within a multi-step pathway having a net conversion of succinyl-CoA to succinate.

11 .- 40 . (canceled)

41 . A non-naturally occurring microbial organism comprising a gene disruption of a gene encoding YciA CoA hydrolase and a metabolically engineered pathway for producing a bioderived compound from a TCA cycle intermediate.

42 .- 70 . (canceled)

71 . A non-naturally occurring microbial organism of claim 10 , wherein said microbial organism is selected from the group consisting of bacteria, yeast, fungus or other microorganism applicable to a fermentation process.

72 .- 73 . (canceled)

74 . A method of producing a bioderived compound comprising culturing a non-naturally occurring microbial organism of claim 10 for a sufficient period of time under conditions sufficient to produce said bioderived compound.

75 . A bioderived compound produced by the non-naturally occurring microbial organism of claim 10 .